Lansing, Michigan — According to state and local development sources, Niowave plans to invest $20,000,000.00 to build out new space in Lansing. The company plans to occupy the new space at 1012 N Walnut St. in Lansing, on or about December 1, 2023. According to the company website Niowave is a domestic supplier of medical and industrial radioisotopes from uranium fission and stable targets. Isotope inventories available for purchase include alpha, beta, and gamma sources. The system uses a superconducting linac instead of a nuclear reactor which is simpler to operate and less costly to license. It also eliminates the need for a nuclear reactor and weapons grade uranium (HEU). The small batch radiochemistry operations can be automated, and do not require licensing as a nuclear reprocessing facility. Isotope production and distribution utilize existing radiopharmaceutical supply chain and FDA approval processes.

To learn more about Niowave, visit http://www.niowaveinc.com/

Company Contact:
Mike Zamiara, President
zamiara@niowaveinc.com
https://www.linkedin.com/in/mike-zamiara-8b676211/
517-999-3475

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.